New gene therapy injection aims to halt vision loss in stargardt disease
Disease control
Recruiting now
This study tests a one-time gene therapy injection (AAVB-039) into the eye for people with Stargardt disease, a genetic condition that causes progressive vision loss. The trial involves 75 participants and will first check safety, then measure if the treatment can slow damage to …
Phase: PHASE1, PHASE2 • Sponsor: AAVantgarde Bio Srl • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC